Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
SiSaf & the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer March 2, 2023
SiSaf Ltd recently announced its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of….
SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame March 1, 2023
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea February 22, 2023
Daré Bioscience, Inc. recently announced the start of a Phase 1 study evaluating its development program targeted at treating primary...SPECIAL FEATURE - Outsourcing Analytical Testing – Timelines, Regulations & Biologics Drive the Sector January 17, 2023
Contributor Cindy H. Dubin interviews leading CDMOs to discuss not just their analytical service offerings, but their strategies for meeting regulatory challenges and ensuring faster project timelines.
FUNCTIONAL EXCIPIENTS - Improving the Water Solubility of Oral Drugs With Amorphous Solid Dispersions (ASDs) January 16, 2023
Liliana Miinea, PhD, says with certain polymers, it is possible for drug formulators to take full advantage of the benefits of ASDs, enabling them to overcome formulation challenges to deliver more effective novel drug products capable of transforming the lives of patients.
IMUNON Enters Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform January 5, 2023
IMUNON, Inc. and The Wistar Institute recently announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the….
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates December 19, 2022
Assembly Biosciences, Inc. recently announced promising interim efficacy, safety and pharmacokinetic (PK) results from two ongoing clinical studies of its...Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria & Provides Business Update December 1, 2022
Synlogic, Inc. recently announced SYNB1353 has achieved proof of mechanism and positive results in a Phase 1 study in healthy...DRUG DELIVERY - Using the IPEG™ Delivery System to Topically Treat Rare Diseases in Dermatology While Limiting Systemic Absorption November 30, 2022
Zachary Rome, Jessica Raiz, MPH, and Alan M. Mendelsohn, MD, are advancing innovative clinical research that is evaluating high-potential, low-risk treatments for rare dermatologic diseases using unique topical vehicles combined with established medications that enable the targeted delivery of therapies to the epidermis and dermis while minimizing systemic absorption.
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients November 30, 2022
Aridis Pharmaceuticals, Inc. recently announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the...Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide October 27, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned...Lonza joins GENEGUT Project to Develop a Capsule Delivery Solution for an Innovative Crohn's Disease Treatment October 25, 2022
Lonza recently announced its participation in the GENEGUT project to develop an innovative functional capsule-based delivery solution for therapies targeting….
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections From Ongoing Phase 3 Study October 24, 2022
SCYNEXIS, Inc. recently announced the presentation of cumulative interim outcomes and all-cause mortality data in patients with refractory candidiasis treated...EXCIPIENT COMPACTION STUDY - Developing a Reliable Controlled-Release Polymer Using a Compaction Simulator October 3, 2022
Gopeshkumar Singh, MS, and Ajit Bhagat provide study results showing that through polymer chemistry, it is viable to effectively manufacture matrix tablets via a simple direct compression method; and Hypromellose has impressive compatibility at various compression forces.
GENFIT to Acquire Clinical-Stage Biopharmaceutical Company, Expanding its Portfolio in Liver Diseases September 19, 2022
GENFIT recently announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting...SiSaf Announces Positive Preclinical Data for its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis September 12, 2022
SiSaf Ltd, an RNA delivery and therapeutics company, recently announce positive data confirming safety and efficacy of its Bio-Courier next-generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an….
EXECUTIVE INTERVIEW - Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics August 31, 2022
Bill Hartzel, Senior Vice President and Head of CDMO Business, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
2022 Analytical Testing eBook – Service Providers Offer Innovation August 23, 2022
Learn more about the technologies from Alcami, Associates of Cape Cod, Stevanato Group, and West in this exclusive 2022 Drug Development & Delivery Analytical Testing e-book.
Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo August 1, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary...Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates August 1, 2022
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...CycloLab Cyclodextrin Research & Development Ltd.
CycloLab Cyclodextrin Research & Development Ltd. E: commerce@cyclolab.hu W: cyclolab.hu LinkedIn: https://www.linkedin.com/company/10040240 For more than 30 years, Cyclolab Ltd. has been involved in...
